LEWISBERRY, Pa., Nov. 15, 2010 /PRNewswire/ — Unilife
Corporation (“Unilife” or “Company”) (Nasdaq:
UNIS; ASX: UNS) today announced that it has commenced U.S.
sales of its Unitract® range of 1mL safety syringes.
Unilife and Independent Medical Co-Op, Inc. (“IMCO”), one of the
largest medical supply co-operatives in the U.S., have entered into
a preferred, non-exclusive marketing program for the sale of
Unitract 1mL syringes to U.S. healthcare facilities.
IMCO’s member distributors provide medical equipment and
supplies to healthcare facilities across the U.S. and Canada. Many
of IMCO’s Members focus primarily on the physician and long-term
care markets. These two segments of the U.S. healthcare market
consume a significant proportion of all 1mL safety syringes
manufactured each year.
Unilife considers IMCO to be an ideal partner to support the
initial launch of its Unitract range of 1mL syringes in the U.S. It
is now processing for shipment a number of initial purchase orders
it has received from IMCO member distributors. Discussions with a
number of additional IMCO members are currently under way as part
of an integrated nationwide launch for the Company’s FDA-certified
range of products.
Mr. Alan Shortall, CEO of Unilife, stated, “Unilife is delighted
to announce the commencement of U.S. sales and shipments for its
Unitract range of 1mL syringes. It is appropriate that U.S. sales
have commenced in the same month that healthcare industry leaders
are celebrating the 10-year anniversary of the signing of the
Federal Needlestick Safety and Prevention Act. Despite these laws
mandating the use of safety syringes within U.S. healthcare
facilities, many healthcare workers continue to remain at risk of
needlestick injury, including injuries from existing safety syringe
technologies. We believe the automatic and operator
controlled safety features
‘/>”/>
SOURCE
